基于专利计量的天麻药品研发态势分析  

Situation analysis of Gastrodia elata drug research and development based on patent metrology

作　　者：上官晨虹 全毅恒 陈琛[1] SHANGGUAN Chen-hong;QUAN Yi-heng;CHEN Chen(Chinese-German Joint Institute for Natural Product Research,Shaanxi University of Technology,Shaanxi Provincial Engineering Research Center of Gastrodia Elata and Cornus Officinalis,Key Laboratory of Bio-resources of Shaanxi Province,College of Biological Science and Engineering,Shaanxi University of Technology,Hanzhong 723000,China)

机构地区：[1]陕西理工大学中德天然产物研究所,陕西省天麻山茱萸工程技术研究中心,陕西省资源生物重点实验室,陕西理工大学生物科学与工程学院,陕西汉中723000

出　　处：《中草药》2022年第15期4915-4924,共10页Chinese Traditional and Herbal Drugs

基　　金：国家高端外国专家项目(GDT20186100426);陕西省重点研发项目(2020NY-139);陕西省创新能力支撑计划项目(2019XY-04)。

摘　　要：天麻Gastrodia elata是我国名贵中药,具有极高的药用和食用价值,拥有巨大的潜在市场,为了解天麻药品专利的特点,掌握其技术研发趋势,以IncoPat数据库和DII数据库为数据源,检索2002年以来国内外公开的天麻药品专利,运用多种专利计量学手段,对申请总量、申请地域、申请机构、主要发明人、专利代理、前沿热点等方面进行分析。结果表明,20年来天麻药品专利数量持续增加;全球天麻药品专利主要源于中国,韩国和美国在未来可能会成为中国的竞争国;国内外申请机构间的合作较少且呈现出较强的地域性;发明人间缺乏跨地区、跨国界的交流;国内杰出的代理机构主要分布在安徽省、山东省、北京市;天麻药品未来的研究热点在治疗血管性偏头痛、高血压及风湿骨病。该研究能为天麻药品专利未来申请布局、产品创新研发及市场战略的制定提供参考,研究人员应当紧抓未来前沿热点,加强省际、国际合作,不断研发出高质量的天麻药品。Gastrodia elata is a precious traditional Chinese medicine, which has high medicinal and edible value, and has a huge potential market. In order to understand the characteristics of G. elata drug patents and grasp its technical research and development trend, IncoPat database and DII database were used as data sources to retrieve the patent of G. elata drugs published at home and abroad since 2002, and a variety of bibliometric methods were used to analyze the patent of G. elata drugs according to the total amount of applications, application areas, application agencies, main inventors, patent agents and frontier hotspots. The results showed that the number of G. elata drug patents has continued to increase in the past 20 years. Global G. elata patent mainly comes from China, and South Korea and the United States may become China’s competitors in the future. The cooperation between domestic and foreign application agencies is less and shows a strong regional. Inventors lack cross-regional and cross-border communication. Domestic outstanding agencies are mainly distributed in Anhui Province, Shandong Province and Beijing. Future research hotspots for G. elata drugs are in the treatment of vascular migraine, hypertension and rheumatic bone disease. This study can provide reference for future patent application layout, product innovation and research and development, and the formulation of market strategy of G. elata drugs.Researchers should pay close attention to future hotspots, strengthen inter-provincial and international cooperation, and continuously develop high-quality G. elata drugs.

关 键 词：天麻 药品 IncoPat数据库 DII数据库 专利计量学 

分 类 号：R288[医药卫生—中药学]